3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
FED
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Hepatocellular
3
Neoplasms
2
Breast Neoplasms
2
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Ototoxicity
1
Heart Failure
1
Endometrial Neoplasms
1
Endometrial Hyperplasia
1
Cardiovascular Diseases
1
Cardiotoxicity
1
Atherosclerosis
1
Interventions
Docetaxel
171
Radiotherapy
144
Magnetic Resonance Spectroscopy
142
Leuprolide
112
Prednisone
108
enzalutamide
102
Radiosurgery
101
Abiraterone Acetate
94
Androgen Antagonists
91
Goserelin
83
bicalutamide
81
gallium 68 PSMA-11
70
Surveys and Questionnaires
63
apalutamide
57
Specimen Handling
56
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
55
Radiation
47
Gonadotropin-Releasing Hormone
45
Standard of Care
44
Biopsy
44
Brachytherapy
42
Radiotherapy, Intensity-Modulated
40
Blood Specimen Collection
40
darolutamide
39
abiraterone
39
cabazitaxel
35
Exercise
35
Carboplatin
33
Pluvicto
32
Triptorelin Pamoate
31
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Prostatic Neoplasms
×
Hydroxymethylglutaryl-CoA Reductase Inhibitors
×
Clear all
NCT03127631
2025-01-31
RADICALPC
McMaster University
Phase NA
Recruiting
6,000 enrolled